Skip to main content
Premium Trial:

Request an Annual Quote

Metaphorics, Syrrx Ink Ligand-Docking Partnership

NEW YORK, March 1 - Bioinformatics company Metaphorics has struck a  research collaboration with drug-discovery firm Syrrx designed to improve computational tools for docking ligand molecule structures into protein binding sites.

The companies said on Thursday that the collaboration seeks to create new software that might help scientists better predict "the potential complementarity" between ligands and proteins.

Metaphorics, of Mission Viejo, Calif., will bring its DockIt distance-geometry-based technology to the table. This technology was designed to automate high-throughput docking of small molecules versus macromolecular targets.

 

In exchange, Syrrx, which has used DockIt in its own research for one year, will provide its experience in compiling and analyzing structural-proteomics data. Syrrx, based in San Diego, said its DockIt software runs on a Linux cluster of nearly 500 nodes, which it said will increase to 1,000 nodes by mid-year.

According to a statement, Metaphorics and Syrrx believe that "the problem of assessing complementarity between ligands and macromolecular targets is a key area for improvements in existing docking methods."

 

Financial details of the deal were not disclosed.

 

"As one of the leaders in the structural proteomics field, Syrrx is in an excellent position to identify necessary advancements in bioinformatics tools," said Scott Dixon, Metaphorics' Chief Technology Officer. "They have built one of the most advanced technology platforms for the determination of protein structures and this makes them an ideal collaborator for the further development of DockIt."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more